| [1] |
Kawarai Y, Orita S, Nakamura J, et al. Analgesic effect of duloxetine on an animal model of monosodium Iodoacetate-Induced hip osteoarthritis[J]. J Orthop Res, 2020, 38(2): 422-430.
|
| [2] |
Hunter DJ, Bierma-Zeinstra S. Osteoarthritis[J]. Lancet, 2019, 393(1182): 1745-1759.
|
| [3] |
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and National incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet (London, England), 2018, 392(10159): 1789-1858.
|
| [4] |
Mcalindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis[J]. Osteoarthritis Cartilage, 2014, 22(3): 363-388.
|
| [5] |
Uchio Y, Enomoto H, Alev L, et al. A randomized, double-blind, placebo-controlled Phase III trial of duloxetine in Japanese patients with knee pain due to osteoarthritis[J]. J Pain Res, 2018, 11: 809-821.
|
| [6] |
Bair MJ, Wu J, Damush TM, et al. Association of depression and anxiety alone and in combination with chronic musculoskeletal pain in primary care patients[J]. Psychosom Med, 2008, 70(8): 890-897.
|
| [7] |
Enteshari-Moghaddam A, Azami A, Isazadehfar K, et al. Efficacy of duloxetine and gabapentin in pain reduction in patients with knee osteoarthritis[J]. Clin Rheumatol, 2019, 38(10): 2873-2880.
|
| [8] |
Chen L, Gong M, Liu G, et al. Efficacy and tolerability of duloxetine in patients with knee osteoarthritis: a meta-analysis of randomised controlled trials[J]. Intern Med J, 2019, 49(12): 1514-1523.
|
| [9] |
Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis[J]. Osteoarthritis Cartilage, 2019, 27(11): 1578-1589.
|
| [10] |
Fitzcharles MA, Lussier D, Shir Y. Management of chronic arthritis pain in the elderly[J]. Drugs Aging, 2010, 27(6): 471-490.
|
| [11] |
Van DJ, Schiphof D, Luijsterburg P, et al. Effectiveness and cost-effectiveness of duloxetine added to usual care for patients with chronic pain due to hip or knee osteoarthritis: protocol of a pragmatic open-label cluster randomised trial (the DUO trial)[J/OL]. BMJ Open, 2017, 7(9): e018661. doi： 10.1136/bmjopen-2017-018661. |
| [12] |
Havelin J, Imbert I, Cormier J, et al. Central sensitization and neuropathic features of ongoing pain in a rat model of advanced osteoarthritis[J]. J Pain, 2016, 17(3): 374-382.
|
| [13] |
Power JD, Perruccio AV, Gandhi R, et al. Neuropathic pain in end-stage hip and knee osteoarthritis: differential associations with patient-reported pain at rest and pain on activity[J]. Osteoarthritis Cartilage, 2018, 26(3): 363-369.
|
| [14] |
Sofat N, Harrison A, Russell MD, et al. The effect of pregabalin or duloxetine on arthritis pain: a clinical and mechanistic study in people with hand osteoarthritis[J]. J Pain Res, 2017, 10：2437-2449.
|
| [15] |
Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents[J]. J Pharmacol Exp Ther, 2005, 312(2): 726-732.
|
| [16] |
Schaible HG. Mechanisms of chronic pain in osteoarthritis[J]. Curr Rheumatol Rep, 2012, 14(6): 549-556.
|
| [17] |
Mease PJ, Hanna S, Frakes EP, et al. Pain mechanisms in osteoarthritis: understanding the role of central pain and current approaches to its treatment[J]. J Rheumatol, 2011, 38(8): 1546-1551.
|
| [18] |
Wang G, Bi L, Li X, et al. Efficacy and safety of duloxetine in Chinese patients with chronic pain due to osteoarthritis: a randomized, double-blind, placebo-controlled study[J]. Osteoarthritis Cartilage, 2017, 25(6): 832-838.
|
| [19] |
Ito S, Suto T, Saito S, et al. Repeated administration of duloxetine suppresses neuropathic pain by accumulating effects of noradrenaline in the spinal cord[J]. Anesth Analg, 2018, 126(1): 298-307.
|
| [20] |
Obata H. Analgesic mechanisms of antidepressants for neuropathic pain[J/OL]. Int J Mol Sci, 2017, 18(11): 2483. doi： 10.3390/ijms18112483. |
| [21] |
Alba-Delgado C, Mico JA, Sánchez-Blázquez P, et al. Analgesic antidepressants promote the responsiveness of locus coeruleus neurons to noxious stimulation: implications for neuropathic pain[J]. Pain, 2012, 153(7): 1438-1449.
|
| [22] |
Chen M, Hoshino H, Saito S, et al. Spinal dopaminergic involvement in the antihyperalgesic effect of antidepressants in a rat model of neuropathic pain[J]. Neurosci Lett, 2017, 649: 116-123.
|
| [23] |
Myers J, Wielage RC, Han B, et al. The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis[J/OL]. BMC Musculoskelet Disord, 2014, 15: 76. doi： 10.1186/1471-2474-15-76. |
| [24] |
Enomoto H, Fujikoshi S, Tsuji T, et al. Efficacy of duloxetine by prior NSAID use in the treatment of chronic osteoarthritis knee pain: a post hoc subgroup analysis of a randomized, placebo-controlled, phase 3 study in Japan[J]. J Orthop Sci, 2018, 23(6): 1019-1026.
|
| [25] |
Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials[J]. Pain Med, 2015, 16(7): 1373-1385.
|
| [26] |
Yamashita T, Yamamoto S, Zhang J, et al. Duloxetine inhibits microglial P2X4 receptor function and alleviates neuropathic pain after peripheral nerve injury[J/OL]. PLoS One, 2016, 11(10): e0165189. doi： 10.1371/journal.pone.0165189. |
| [27] |
Kremer M, Yalcin I, Goumon Y, et al. A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline[J]. J Neurosci, 2018, 38(46): 9934-9954.
|
| [28] |
Choi HS, Park JH, Ahn JH, et al. The anti-inflammatory activity of duloxetine, a serotonin/norepinephrine reuptake inhibitor, prevents kainic acid-induced hippocampal neuronal death in mice[J]. J Neurol Sci, 2015, 358(1/2): 390-397.
|
| [29] |
Ohgi Y, Futamura T, Kikuchi T, et al. Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration[J]. Pharmacol Biochem Behav, 2013, 103(4): 853-859.
|
| [30] |
Bayram FO, Reis R, Tuncer B, et al. The importance of the structural similarity of drugs used for depression and inflammation，two comorbid diseases[J]. Curr Top Med Chem, 2018, 18(16): 1416-1421.
|
| [31] |
Wang G, Bi L, Li X, et al. Maintenance of effect of duloxetine in Chinese patients with pain due to osteoarthritis: 13-week open-label extension data[J/OL]. BMC Musculoskelet Disord, 2019, 20(1): 174.doi： 10.1186/s12891-019-2527-y. |
| [32] |
Itoh N, Tsuji T, Ishida M, et al. Response to duloxetine in patients with knee pain due to osteoarthritis: an exploratory post hoc analysis of a Japanese Phase III randomized study[J]. J Pain Res, 2018, 11: 2603-2616.
|
| [33] |
Fujii T, Takana K, Orita S, et al. Progressive change in joint degeneration in patients with knee or hip osteoarthritis treated with fentanyl in a randomized trial[J]. Yonsei Med J, 2014, 55(5): 1379-1385.
|
| [34] |
Uchio Y, Enomoto H, Ishida M, et al. Safety and efficacy of duloxetine in Japanese patients with chronic knee pain due to osteoarthritis: an open-label, long-term, Phase III extension study[J]. J Pain Res, 2018, 11: 1391-1403.
|
| [35] |
Osani MC, Bannuru RR. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis[J]. Korean J Intern Med, 2019, 34(5): 966-973.
|
| [36] |
Micca JL, Ruff D, Ahl J, et al. Safety and efficacy of duloxetine treatment in older and younger patients with osteoarthritis knee pain: a post hoc, subgroup analysis of two randomized, placebo-controlled trials[J/OL]. BMC Musculoskelet Disord, 2013, 14(1): 137. doi： 10.1186/1471-2474-14-137. |
| [37] |
Brown JP, Boulay LJ. Clinical experience with duloxetine in the management of chronic musculoskeletal pain. A focus on osteoarthritis of the knee[J]. Ther Adv Musculoskelet Dis, 2013, 5(6): 291-304.
|
| [38] |
Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants[J]. CNS Drugs, 2012, 26(1): 39-67.
|